PIONEERING WHAT'S NEXT

Paving the way forward through clinical evidence.

Quantgene is actively engaged in multiple clinical trials and research studies to understand and validate the application of our technology to the full range of challenges in medicine.

CLINICAL TRIALS IN EARLY DETECTION

Quantgene is engaged in two trials to validate the early cancer detection capabilities of our technology. We are excited to announce that we see promising interim results from our feasibility trial. Contact us to learn more about our clinical trials.

CLINICAL FEASIBILITY TRIAL

Currently Enrolling

Since 2015, Quantgene has been aggregating clinical samples in a 10,000 patient feasibility study to determine the accuracy of QUANTUM ARRAY.

Over 12 Clinical Sites
10,000 Patient Target
Over 90% Accuracy

We have partnered with some of the leading clinical institutions throughout the United States and Europe, with many more in the pipeline.

One of the largest studies in cFDNA and multi-cancer detection.

Download the Interim Analysis Presentation

Interim results show >90% sensitivity and specificity for select stage I & II cancers.

In Development
(enrollment expected to begin Q1 2020)

Large population-based study of 20,000 people to validate QUANTUM ARRAY as a multi-cancer screening tool.

Target of 20,000 People

Large target size will allow validation of multi-cancer screening capabilities.

Registry Development

Quantgene is exploring establishing a registry of all study participants.

PLATFORM EVOLUTION RESEARCH

Quantgene is actively engaged in research to explore the application of our technology to the full continuum of cancer as well as diseases beyond cancer.

We are interested in expanding our network of research partners, including research proposals and possible partial funding considerations. Contact us to learn more about our clinical trials.

Over 12 Clinical Sites
Over 90% Accuracy
Currently Enrolling
(for some cancers in pilot studies)
In Development
In Development

We are researching the full course of disease in cancer including early detection, minimal residual disease, recurrence detection and tissue typing.

We are joining with clinical oncology partners to establish our technology for use in high-risk patient screening.

10,000 Patient Target
Meet Our Team of Experts

We are planning research for patient disease profiling and reversibility in a range of diseases.